Researchers at the Icahn School of Medicine at Mount Sinai have developed an advanced artificial intelligence (AI)-driven tool to improve the management and prognosis of prostate cancer. Recent ...
A new study is set to investigate how AI could significantly improve doctors’ decisions regarding prostate cancer treatment. While diagnostic methods for the disease have become safer and more precise ...
California-based Artera, a company that develops multimodal AI-based prognostic and predictive cancer tests, has been granted de novo authorization by the FDA for its AI tool for prostate cancer ...
ArteraAI Prostate is now an FDA-regulated software (as a medical device) to estimate long-term outcomes and predict the benefit of hormone therapy for individual patients with localized prostate ...
Researchers have developed a simple new tool that can identify the risk level of metastatic prostate cancer patients earlier. At the time of diagnosis, the test can predict how well the patient will ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers ...
PSMA PET-CT is a diagnosit tool helping save men's lives with prostate cancer that has spread beyond the prostate gland Dr. David Samadi says that men with aggressive prostate cancer or a very high ...
A new study is set to investigate how AI could significantly improve doctors’ decisions regarding prostate cancer treatment. While diagnostic methods for the disease have become safer and more precise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results